论文部分内容阅读
目的:探讨丹参川芎嗪注射液对不稳定型心绞痛(UA)患者血浆可溶性CD40配体(sCD40L)浓度的影响。方法:将入选的150例UA患者,随机分为2组,对照组72例,给予硝酸酯类药物、阿司匹林、他汀类药物等常规治疗;治疗组78例,在常规治疗基础上加用丹参川芎嗪注射液,每天10mL。连续用药2周。分别于入院时及用药2周末测定血小板计数、血脂、血糖、血清C反应蛋白(CRP)、sCD40L水平。结果:治疗组治疗前后血小板计数比较,差异有显著性意义(P<0.05)。2组治疗后血小板计数比较,差异有显著性意义(P<0.05)。治疗后2组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)水平升高(P<0.05)。治疗组与对照组比较,TC、TG、LDL-C水平下降更显著,差异均有显著性意义(P<0.05),HDL-C水平升高更显著,差异有显著性意义(P<0.05)。治疗后2组CRP水平较治疗前明显下降,差异有显著性意义(P<0.05)。治疗后治疗组CRP水平下降较对照组更显著,差异有显著性意义(P<0.05)。2组治疗后sCD40L水平均较治疗前明显下降,差异有显著性意义(P<0.05)。治疗组sCD40L水平下降较对照组更显著,差异有显著性意义(P<0.05)。结论:丹参川芎嗪注射液通过减轻炎症反应、抗血小板聚集、抑制血栓形成、调脂等作用稳定斑块,使UA患者受益,改善预后。
Objective: To investigate the effect of ligustrazine injection on plasma soluble CD40 ligand (sCD40L) in patients with unstable angina pectoris (UA). Methods: The 150 UA patients were randomly divided into two groups, the control group of 72 patients, given nitrates, aspirin, statins and other conventional treatment; the treatment group of 78 patients on the basis of conventional treatment plus Salvia Chuanxiong Triazine injection, 10mL daily. Continuous medication for 2 weeks. Platelet count, blood lipid, blood glucose, serum C-reactive protein (CRP), sCD40L levels were measured at admission and 2 weeks after treatment. Results: The difference of platelet count before and after treatment in the treatment group was significant (P <0.05). The difference of platelet count between the two groups after treatment was significant (P <0.05). After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) decreased and the levels of high density lipoprotein cholesterol (HDL-C) <0.05). Compared with the control group, the levels of TC, TG and LDL-C in the treatment group decreased significantly (P <0.05), and the levels of HDL-C increased more significantly (P <0.05) . After treatment, the levels of CRP in the two groups were significantly lower than those before treatment, the difference was significant (P <0.05). After treatment, the treatment group CRP level decreased more significantly than the control group, the difference was significant (P <0.05). The sCD40L levels in both groups were significantly lower than those before treatment, the difference was significant (P <0.05). The level of sCD40L in the treatment group decreased more significantly than that in the control group, with significant difference (P <0.05). Conclusion: Salviae miltiorrhizae injection can stabilize the plaque by reducing the inflammatory reaction, anti-platelet aggregation, inhibiting thrombosis, regulating lipid regulation and so on, thus benefiting UA patients and improving prognosis.